Oral Oncology
Volume 46, Issue 7 , Pages 514-518 , July 2010

Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer

  • Pratikshya Pradhan-Palikhe

      Affiliations

    • Department of Oral and Maxillofacial Diseases, Institute of Dentistry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    • These authors contributed equally to this work.
    • ,
  • Tiina Vesterinen

      Affiliations

    • Department of Otorhinolaryngology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 4 E, P.O. Box 220, 00029 HUS, Finland
    • These authors contributed equally to this work.
    • ,
  • Jussi Tarkkanen

      Affiliations

    • Department of Pathology, Helsinki University Central Hospital, Finland
    • ,
  • Ilmo Leivo

      Affiliations

    • Department of Pathology, Helsinki University Central Hospital, Finland
    • ,
  • Timo Sorsa

      Affiliations

    • Department of Oral and Maxillofacial Diseases, Institute of Dentistry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • Tuula Salo

      Affiliations

    • Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu and Oulu University Hospital, Finland
    • ,
  • Petri S. Mattila

      Affiliations

    • Department of Otorhinolaryngology, University of Helsinki and Helsinki University Central Hospital, Haartmaninkatu 4 E, P.O. Box 220, 00029 HUS, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 50 4271560.

Received 20 January 2010 ,Revised 3 March 2010 ,Accepted 4 March 2010.

References 

  1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–174
  2. Korpi JT, Kervinen V, Mäklin H, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008;98(4):766–775
  3. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 2004;64(5):1687–1694
  4. Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008;8:77
  5. Decock J, Long JR, Laxton RC, et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67(21):10214–10221
  6. McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999;84(1):44–48
  7. Schrohl AS, Christensen IJ, Pedersen AN, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics. 2003;2(3):164–172
  8. Lipton A, Leitzel K, Chaudri-Ross HA, et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008;26(16):2653–2658
  9. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6(11):4292–4299
  10. Holten-Andersen MN, Fenger C, Nielsen HJ, et al. Plasma TIMP-1 in patients with colorectal adenomas: a prospective study. Eur J Cancer. 2004;40(14):2159–2164
  11. Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology. 2007;72(3–4):205–208
  12. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer. 2006;42(12):1889–1896
  13. Sorensen NM, Byström P, Christensen IJ, et al. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res. 2007;13(14):4117–4122
  14. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer. 2005;103(8):1676–1684
  15. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer. 2003;39(13):1948–1956
  16. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res. 2005;11(9):3257–3264
  17. Lundberg M, Pajusto M, Koskinen WJ, Mäkitie AA, Aaltonen LM, Mattila PS. Association between transforming growth factor beta1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer. Head Neck. 2009;31(5):664–672
  18. Hanemaaijer R, Sorsa T, Konttinen YT, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem. 1997;272(50):31504–31509
  19. Tuomainen AM, Nyyssönen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007;27(12):2722–2728
  20. Anderson CL, Brown CJ. Polymorphic X-chromosome inactivation of the human TIMP1 gene. Am J Hum Genet. 1999;65(3):699–708
  21. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997;3(9):1623–1628
  22. Nakopoulou L, Giannopoulou I, Stefanaki K, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol. 2002;197(3):307–313
  23. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004;10(7):2289–2298
  24. Gonzalez LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007;97(7):957–963
  25. Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96(6):903–911
  26. Inoue H, Mimori K, Shiraishi T, et al. Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol Rep. 2000;7(4):871–874
  27. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res. 1995;1(8):899–906
  28. Fong KM, Kida Y, Zimmerman PV, Smith PJ. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res. 1996;2(8):1369–1372
  29. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76(4):531–536
  30. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer. 1992;66(6):1188–1194
  31. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res. 1993;5(1):19–28
  32. Kossakowska AE, Urbanski SJ, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin’s lymphomas. Blood. 1991;77(11):2475–2481
  33. Clavel C, Polette M, Doco M, Binninger I, Birembaut P. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer. 1992;79(3):261–270
  34. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189(2):161–168
  35. Holten-Andersen MN, Hansen U, Brunner N, Nielsen HJ, Illemann M, Nielsen BS. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer. 2005;113(2):198–206
  36. Christopoulos TA, Papageorgakopoulou N, Ravazoula P, et al. Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. Oncol Rep. 2007;18(4):855–860
  37. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005;104(10):2282–2287
  38. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25(1):99–113
  39. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008;1(27):re6
  40. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298(1):29–32
  41. Harrison-Lavoie KJ, Michaux G, Hewlett L, et al. P-selectin and CD63 use different mechanisms for delivery to Weibel-Palade bodies. Traffic. 2006;7(6):647–662
  42. Yoshiji H, Harris SR, Raso E, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer. 1998;75(1):81–87
  43. Kim YS, Hwang SY, Kang HY, et al. Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1. Mol Cell Proteomics. 2008;7(1):1–14
  44. Zacchigna S, Zentilin L, Morini M, et al. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2004;11(1):73–80

PII: S1368-8375(10)00091-6

doi: 10.1016/j.oraloncology.2010.03.002

Oral Oncology
Volume 46, Issue 7 , Pages 514-518 , July 2010

Article Tools

* Image Usage & Resolution